logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis Says Gilenya Showed Positive Clinical Outcomes In Phase III 2309 Study

Novartis AG (NVS) announced new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis, or RRMS, treated with Gilenya, or fingolimod, had a statistically significant 48% reduction in annualized relapse rates at 24 months compared to placebo.

According to the company, study 2309 is the third Phase III clinical trial to demonstrate a significant reduction of relapse rates with Gilenya treatment in patients with RRMS.

Novartis noted that a reduction of brain volume loss, a pre-defined key secondary endpoint for study 2309, also achieved statistical significance for Gilenya-treated patients compared to placebo. Brain volume loss is valued as a predictor of long-term disability.

Moreover, safety and tolerability were broadly consistent with previous clinical trials.

"Study 2309 confirms the efficacy of Gilenya across several key measures, including reductions in annualized relapse rate and reductions in brain volume loss," said David Epstein, Head of the Pharmaceuticals Division at Novartis Pharma AG. "With more than 20,000 patient years of fingolimod exposure to date, Gilenya continues to demonstrate its value to patients and the MS community. We are looking forward to presenting the full data to the clinical community at a scientific congress next year."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc. on Tuesday introduced the latest generation of its flagship Fire tablet - the Fire HD 10. The new tablet comes with a 10.1 inch widescreen, 1080p display, ten hours of battery life, and Alexa hands-free capabilities. The Fire HD 10 is available for pre-order beginning today with 32GB or 64GB of internal storage, and starting at $149.99. Rite Aid Corp. and Walgreens Boots Alliance Inc. have secured regulatory clearance for an amended and restated purchase agreement, under which Walgreens will buy 1,932 stores, three distribution centers and related inventory from Rite Aid for $4.375 billion in cash. Department store operator Kohl's Corp. said that it will offer free, convenient returns for Amazon.com Inc. customers in 82 of its stores across Los Angeles and Chicago, starting in October. Kohl's will pack and ship eligible Amazon return items for free to Amazon return centers, thus providing an additional service and convenience to Amazon customers within select Kohl's stores.
comments powered by Disqus
Follow RTT